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Background: p57Kip2, a cyclin-dependent kinase inhibitor, is considered to be a candidate tumor suppressor gene that
has been implicated in Beckwith-Wiedemann syndrome and sporadic cancers. In addition, decreased expression of
p57Kip2 protein has been frequently observed in pancreatic, lung, breast, bladder, gastrointestinal tract and prostate
cancers. However, p57Kip2 gene mutations are rare in these cancers suggesting that other unknown mechanisms might be
at play in reducing its expression. The aim of this study was to investigate the molecular mechanism of down-regulation of
p57Kip2 in prostate cancer.
Findings: We observed a significant negative correlation between the expression of p57Kip2 and microRNA-21 (miR-21) in
prostate cancer samples and after androgen deprivation with castration in the CWR22 human prostate cancer xenograft
model. We report that miR-21 targeted the coding region and decreased p57Kip2 mRNA and protein levels in prostate
cancer cells. Conversely, inhibition of endogenous miR-21 by an anti-miR-21 inhibitor strongly induced p57Kip2 expression.
Furthermore, we found that knockdown of p57Kip2 reversed the effects of the anti-miR-21 inhibitor on cell migration and
anchorage-independent cell growth.
Conclusions: Our results indicate that miR-21 is able to downregulate p57Kip2 expression by targeting the coding region
of the gene and is also able to attenuate p57Kip2 mediated functional responses. This is the first report demonstrating that
p57Kip2 is a novel target of miR-21 in prostate cancer and revealing a novel oncogenic function of this microRNA.
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Uncontrolled cell proliferation due to aberrant regulation
of cell cycle control can lead to the development of
cancer. Cyclin dependent kinase inhibitors (CKIs) are
the common inhibitors of cell cycle which consists of
two families: INK4 family (consisting of p16INK4a,
p15INK4b, p18INK4c and p19INK4d) and Cip/Kip family
(p21CIP1/WAF1, p27Kip2 and p57Kip2) [1]. Human p57Kip2
gene is maternally expressed and paternally imprinted and
is located on chromosome 11p15.5 [2], which is implicated
in Beckwith-Wiedemann syndrome [3] and in sporadic
cancers. p57Kip2 is also required for normal development
as p57Kip2 null mice die at 2 weeks of age and show
increased apoptosis and delayed differentiation during* Correspondence: sunl@uthscsa.edu
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unless otherwise stated.mouse development [4]. Because of its chromosomal
location, imprinting status and functional activities,
p57Kip2 is considered to be a candidate tumor suppressor
gene. p57Kip2 overexpression in LNCaP prostate cancer
cells resulted in the conversion of adenocarcinoma to a
more differentiated squamous tumor in nude mice, with
reduced cell proliferation and tumor invasion [5]. p57Kip2
is considered to be a tumor suppressor gene since it
functions to block cell proliferation by inhibiting cell cycle
progression, promotes apoptosis and cell differentiation,
inhibits tissue invasion and metastasis and also inhibits
angiogenesis [6]. Hence, cancer cells frequently down-
regulate p57Kip2 in order to gain a proliferative advantage.
Loss of or reduced p57Kip2 expression occurs in carcin-
omas of the prostate, bladder, liver, pancreas, breast and
others. The absence of p57Kip2 gene mutations in a wide
variety of cancers suggests that other transcriptional or
post-transcriptional mechanisms might be involved in its
down-regulated protein expression. Inactivation of p57Kip2
gene due to promoter DNA methylation was observed inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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of B-cells [7,8]. Yang et al. found that p57Kip2 expression
in breast cancer cells was repressed due to Polycomb
protein EZH2-mediated H3K27me3 chromatin mark.
Increased p57Kip2 degradation due to ubiquitylation by E3
ligase Skp1/ Cul1/ F-box (SCF complex) was observed
in non-small cell lung carcinoma and hepatocellular
carcinoma [9,10].
Mature miRNAs are ~22 nucleotides long non-coding
single-stranded RNAs, which upon binding to the 3’-UTR
region of target mRNAs can result in mRNA cleavage, or
translational repression. p57Kip2 has been reported to be
targeted by miR-221/222 cluster in gastric carcinoma,
ovarian cancer and hepatocellular carcinoma [11]. miR-92b
and miR-25 have also been reported to down-regulate
p57Kip2 expression in human embryonic stem cells and in
gastric cancer respectively [12,13]. Jin et al. demonstrated
that expression of p57Kip2 is significantly decreased in
human prostate cancer and overexpression of p57Kip2 in
prostate cancer cells decreased cell proliferation and
reduced invasiveness [5]. However, the mechanism behind
p57Kip2 down-regulation in prostate cancer cells has not
been investigated. Unexpectedly, we discovered that p57Kip2
is one of the novel downstream target genes of miR-21 in
prostate cancer. We observed a very strong negative
correlation between p57Kip2 and miR-21 expression in
human prostate tumor samples and in CWR22, a human
prostate cancer xenograft model. Our results for the first
time show that miR-21 can down-regulate p57Kip2 mRNA
and protein expression by targeting its coding region
to attenuate its activity in prostate cancer cells. Thus,
therapeutic approaches aimed at restoring p57Kip2 expres-
sion might be beneficial for prostate cancer prevention
and therapy.
Findings and discussion
MicroRNA-21 targets p57Kip2 gene
Inactivation of p57Kip2 is commonly observed in cancers.
MicroRNAs offer another layer of complexity to the regu-
lation of its gene expression. Recently, microRNAs
(miR-221/222, miR-25, miR-92b) were reported to
downregulate the expression of p57Kip2 transcript [13,14].
In our studies, we found a very significant p57Kip2 down-
regulation in human prostate tumor samples compared to
the normal prostate cells in consistence with the published
studies [5,15]. However, the mechanism of p57Kip2 repres-
sion has not been well studied in prostate cancer. We
along with others have shown a significant upregulation in
miR-21 expression in prostate cancer [16,17]. Surprisingly,
we found a significant (P < 0.05) inverse correlation between
miR-21 and p57Kip2 expression in human prostate cancer
samples downloaded from the Cancer Genome Atlas
(TCGA) database (Figure 1A). We also checked miR-21
expression in different prostate cancer cells and found thatall the cells expressed miR-21 albeit at different levels. Cells
with relatively higher miR-21 levels such as MDA-PCa-2b
and 22Rv1 expressed lower levels of p57Kip2 when
compared to PC-3 cells that expressed relatively low
miR-21 and higher p57Kip2 (Figure 1B). Hence, we
hypothesized that p57Kip2 may be a downstream target
gene of miR-21 in prostate cancer. Regulation of target
genes by binding of microRNA’s to the 3' untranslated
regions (UTRs) of their mRNA’s has been well character-
ized. Hence, most of the bioinformatics tools available to
predict miRNA target sites on mRNAs have been mainly
focused on target sites within the 3'-UTRs of genes. A
study by Hausser et al. suggest that miRNAs may combine
targeting of coding regions and 3’ UTRs to flexibly tune
their post-transcriptional regulatory effects [18]. Available
microRNA prediction target algorithms did not predict
p57Kip2 gene to be targeted by miR-21. However, scanning
of human p57Kip2 gene for the miR-21 recognition site,
revealed a 5-mer complementary binding site to the 2-7
seed region of mature miR-21 and a 3-mer sequence
complementary to the 3’-target site (18-20 nucleotide) in
the coding region of p57Kip2, which is from nucleotides
1054 to 1077 in accession # NM_00007 of GenBank as
shown in Figure 1C. To experimentally test if miR-21
targets p57Kip2, we cloned this putative miR-21 recognition
sequence of p57Kip2 in the 3’-UTR region of the luciferase
gene in the pMIR reporter vector. Transfection of miR-21
mimic in PC-3 prostate cancer cells significantly (P < 0.01)
reduced the luciferase activity (Figure 1D). However, muta-
tion of the putative miR-21 binding nucleotides (Figure 1C
and Additional file 1) abolished this effect. Similarly, lucifer-
ase activity was significantly (P < 0.01) increased when
22Rv1 prostate cancer cells, which were previously also
shown to express relatively high endogenous miR-21 [16],
were transfected with an anti-miR-21 to inhibit the
endogenous miR-21 levels (Figure 1D), and the mutation of
the miR-21 binding sites abrogated this effect.
MicroRNA-21 downregulates p57Kip2 expression
To further validate these findings, we checked the effect
of miR-21 on p57Kip2 mRNA and protein levels. Inhibition
of endogenous miR-21 with an anti-miR-21 in 22Rv1 and
MDA-PCa-2b cells increased the p57Kip2 mRNA levels
(P < 0.05), whereas miR-21 mimic decreased (P < 0.001) the
basal level of p57Kip2 in PC-3 cells (Figure 2A). Transfection
of anti-miR-21 in 22Rv1 and MDA-PCa-2b cells increased
the p57Kip2 protein expression and miR-21 mimic transfec-
tion in PC-3 decreased p57Kip2 expression (Figure 2B). We
used a CWR22 xenograft mouse model to study the effect
on microRNA-21 and p57Kip2 expression under androgen
depletion with castration [19]. We have previously shown
that castration led to down-regulation of miR-21 as
androgen signaling was shown to stimulate miR-21
[16]. We harvested tumors for miR-21 and p57Kip2
Figure 1 MicroRNA-21 targets p57Kip2 gene. (A) miR-21 and p57Kip2 are inversely correlated in 37 matched normal (N) and tumor (T) samples
downloaded from the TCGA database. r: Pearson product-moment correlation coefficient. ****P < 0.0001 with one-way analysis of variance. (B) miR-21
(left panel) and p57Kip2 (right panel) levels were measured in prostate cancer cells with real-time RT-PCR and western blotting respectively. *P < 0.05
with one-way analysis of variance test. (C) Sequence alignment between miR-21 seed sequence and a partial coding or mutated sequence of p57Kip2.
(D) Luciferase assay was performed with miR-21 mimic or anti-miR-21 transfection in cells with co-transfection of pMIR-3’UTR- p57Kip2 or
pMIR-3’UTR-mutated p57Kip2 and a ß-Gal expression construct. **P < 0.01 with one-way analysis of variance and Tukey-Kramer post hoc test.
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respectively. The results showed a significant (P < 0.0001)
decrease in miR-21 expression levels in the castrated mice
when compared to control non-castrated mice (Figure 2C)
as was observed in our previous study. Interestingly, we
observed an increase in p57Kip2 expression at 14 and
40 days in the castrated mice showing an inverse correlationbetween miR-21 and p57Kip2 expression in vivo (Figure 2C)
(P < 0.0001). We show that for the first time, castration-
mediated miR-21 decreases correlate with an increase in
p57Kip2 under in vivo conditions. Currently, it is not clear
how androgen/AR signaling regulates p57Kip2 expression in
prostate cancer cells. Our results suggest that androgen/AR
signaling-mediated inhibition of p57Kip2 expression appears
Figure 2 MicroRNA-21 downregulates p57Kip2 in prostate cancer cells. (A) 22Rv1 and MDA-PCa-2b cells were transfected with the inhibitor
negative control and anti-miR-21 (50 nM) for 48 h. PC-3 cells were transfected with control siRNA and miR-21 mimic (20 nM) for 48 h. p57Kip2
gene expression was checked by real-time RT-PCR. *P < 0.05 and ***P < 0.001 with a Student’s t-test analysis. (B) Cell lysates were used for Western
analysis to measure the level of p57Kip2 and GAPDH after anti-miR-21 inhibitor or miR-21 mimic transfection for 48 h. (C) p57Kip2 and miR-21 expressions
were analyzed in CWR22 tumors after 14 and 40 days of castration. ****P < 0.0001 with one-way analysis of variance test.
Mishra et al. Molecular Cancer 2014, 13:212 Page 4 of 6
http://www.molecular-cancer.com/content/13/1/212to be mediated by miR-21 in CWR22 human prostate
cancer xenografts. Further studies are needed to
understand whether p57Kip2 expression contributes to
castration-induced regression of prostate cancer.
MicroRNA-21 abrogates p57Kip2-mediated functional
responses in prostate cancer cells
p57Kip2 has been shown previously to act as a tumor
suppressor gene by inhibiting cell migration and invasion
[20]. Hence, we tested whether endogenous miR-21
functionally abrogated p57Kip2 mediated tumor suppressive
responses in prostate cancer cells. When we inhibited the
endogenous miR-21 in PC-3 cells with an anti-miR-21
inhibitor, we observed an induction in p57Kip2 expression
(Figure 3A). However, co-transfection with a p57Kip2
small-interfering RNA with anti-miR-21 inhibitor abolished
the p57Kip2 induction by anti-miR-21 (Figure 3A). We also
found that p57Kip2 inhibition significantly increased the cell
migration in both PC-3 and 22Rv1 cells (Figure 3B).
Transfection of cells with an anti-miR-21 inhibitor
decreased the cell migration, although the results were
not statistically significant. Interestingly, we found that theco-transfection of cells with anti-miR-21 and p57Kip2
siRNA, significantly increased cell migration when
compared to anti-miR-21 treatment alone (Figure 3B)
(P < 0.05 and P < 0.01). Similarly, while knocking down of
endogenous miR-21 significantly reduced anchorage-
independent growth, knocking down p57Kip2 reversed the
inhibitory effect of the anti-miR-21 inhibitor on the
anchorage-independent cell growth (Figure 3C) (P < 0.01
and P < 0.001). These results show that the functional
effects of miR-21 in prostate cancer cells could be mediated
partly by a downregulation in p57Kip2 expression.
In summary, we discovered p57Kip2 to be a novel target
gene of microRNA-21 in prostate cancer. Our findings
provide a novel mechanism of p57Kip2 downregulation in
prostate cancer. These findings warrant further research to
test if p57Kip2 is also a novel target gene of miR-21 in other
cancer types as well. In our previous study, we found
miR-21 to be an oncogenic regulator in prostate cancer by
targeting the tumor suppressive effects of TGF-beta
signaling pathway in cancer cells [16]. Given, the
regulation of p57Kip2 by microRNA-21 in the current
study, we provide a strong rationale to perform preclinical
Figure 3 MicroRNA-21 attenuates p57Kip2 mediated functional responses in prostate cancer cells. Cells were transfected with 50 nM of
control siRNA, anti-miR-21 or p57Kip2 siRNA either alone or in combination for 48 h. Cells were trypsinized and replated for Western analysis, cell
migration or soft agar assay. (A) Western analysis in PC-3 cells for p57Kip2 and GAPDH was performed. (B) Number of cells migrated were quantified.
*P < 0.05 and **P < 0.01 with one-way analysis of variance test. (C) After 14 days, colonies were stained and quantified in PC-3 and 22Rv1 cells for
soft-agar colony formation assay. *P < 0.05, **P < 0.01 and ***P < 0.001 with one-way analysis of variance test.
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drug for prostate cancer.Additional file
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